<DOC>
	<DOCNO>NCT00533065</DOCNO>
	<brief_summary>The plan study two purpose : 1 . It provide evidence administration cholinesterase inhibitor result increase IGF-I ( primary variable ) increase secretion growth hormone ( secondary variable ) maintain throughout treatment-period one year . 2 . The study also test hypothesis maintenance increase blood level growth hormone IGF-I stop delay age-related change body composition ( secondary variable ) .</brief_summary>
	<brief_title>Effects Donepezil Deficits Associated With Age-Related Decrease Growth Hormone</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Aged 70 80 year Cardiac arrhythmia ( sick sinus syndrome , AV block , sinoatrial block ) , Treatment betablockers , NSAIDs cholinergic agonist , Known hypersensitivity donepezil hydrochloride , piperidine derivative excipients use formulation , Gastric duodenal ulcer , Severe renal hepatic impairment , Urinary congestion ( prostatic hypertrophy ) , Obstructive pulmonary disease ( bronchial asthma ) ;</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Aging</keyword>
</DOC>